Subjects: ERN, TRI, ANW
Tikcro Technologies Reports Fourth Quarter and Year End 2017 Results
NESS-ZIONA, Israel, March 5, 2018 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, today reported its financial results for the fourth quarter and full year ended December 31, 2017.
Aviv Boim, CEO of Tikcro, commented, "We continue to promote a full human cytotoxic T lymphocyte-associated antigen 4 ("CTLA-4") blocking antibody, currently in small animal efficacy models for cancer treatment. This antibody shows strong results in cancer inhibition animal models. Further, we plan to pursue additional pre-clinical work through 2018 to support regulatory applications for the commencement of clinical trials."
The CTLA-4 blocking antibody approved market is for the treatment of melanoma. The market size for CTLA-4 blocking antibodies exceeds $1 billion per annum. Several pharma companies, including Tikcro, are pursuing new CTLA-4 antibodies to broaden its clinical scope and to reduce its immune related adverse effects.
Financial Results for the Fourth Quarter Ended December 31, 2017
Net loss for the fourth quarter of 2017 was $277,000, or $0.03 per diluted share, compared to a net loss of $340,000, or $0.03 per diluted share, for the same period last year.
Financial Results for the Year Ended December 31, 2017
Net loss for the year ended December 31, 2017 was $1,251,000, or $0.13 per diluted share, compared to a net loss of $1,280,000, or $0.13 per diluted share, for the year ended December 31, 2016.
As of December 31, 2017, the Company had a cash and cash equivalents balance of $6.6 million.
About Tikcro Technologies
Tikcro Technologies Ltd. (OTCQB: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro's website at www.tikcro.com.
Safe Harbor Statement
Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the risks related to early stage biotechnology projects, including, but not limited to, obtaining required licenses at reasonable commercial terms, the development, testing, regulatory approval and commercialization of our proposed products, intellectual property rights, competition, exposure to lawsuits and dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Form 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods. We undertake no duty to update any forward-looking information.
|
Tikcro Technologies Ltd. Condensed Balance Sheets (US dollars in thousands) | ||||||||||
|
December 31, Unaudited |
December 31, Audited |
|||||||||
|
Assets |
||||||||||
|
Current assets |
||||||||||
|
Cash and cash equivalents |
$ |
6,562 |
$ |
7,507 |
||||||
|
Receivables and other financial asset |
21 |
89 |
||||||||
|
Total current assets |
6,583 |
7,596 |
||||||||
|
Property and equipment, net |
125 |
136 |
||||||||
|
Total assets |
$ |
6,708 |
$ |
7,732 |
||||||
|
Liabilities and Shareholders' Equity |
||||||||||
|
Current liabilities |
||||||||||
|
Other current liabilities |
$ |
309 |
$ |
237 |
||||||
|
Shareholders' equity |
6,399 |
7,495 |
||||||||
|
Total liabilities and shareholders' equity |
$ |
6,708 |
$ |
7,732 |
||||||
|
Tikcro Technologies Ltd. |
||||||||||
|
Three Months Ended |
Year Ended | |||||||||
|
2017 |
2016 |
2017 |
2016 | |||||||
|
Research and development expenses |
$ |
145 |
$ |
163 |
$ |
678 |
$ |
601 | ||
|
General and administrative |
171 |
176 |
618 |
676 | ||||||
|
Total operating expenses |
316 |
339 |
1,296 |
1,277 | ||||||
|
Operating loss |
(316) |
(339) |
(1,296) |
(1,277) | ||||||
|
Financial income (expenses), net |
39 |
(1) |
45 |
(3) | ||||||
|
Net loss |
$ |
(277) |
$ |
(340) |
$ |
(1,251) |
$ |
(1,280) | ||
|
Basic and diluted net loss per share |
$ |
(0.03) |
$ |
(0.03) |
$ |
(0.13) |
$ |
(0.13) | ||
|
Weighted average number of |
9,879 |
9,879 |
9,879 |
9,879 | ||||||
SOURCE Tikcro Technologies Ltd.
These press releases may also interest you
|
News published on and distributed by:
